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Summary A bioassay has been developed to detect and quantify the concentration of cytotoxic metabolites
of cyclophosphamide (CY) in blood, tumour, and lungs of mice. Extracts were made of blood or solid tissues
taken from mice given CY and these were used to treat log phase Chinese Hamster V79 cells in culture for up
to 24h. The amount of cell killing was tested by colony formation 7 days later. The effects of incubation
time, CY dose, and the time of tissue sampling after CY injection were investigated.
The bioassay could detect cytotoxic metabolites in blood after doses as low as 10mgkg-1 CY given i.p.
The half life of these metabolites in blood after giving 400mgkg 1 i.p. decreased over a 2h period from 14 to
9min. The method was then modified to define the pharmacokinetics of CY metabolites in two different types
of tumour and in lung. The half life of the cytotoxic metabolites in the lung was longer than in blood, falling
from 35 to 11 min over a 2h period. In tumours, the half lives were longer again, i.e. -61 min. The maximum
metabolite levels achieved were similar in the two tumour types, although these differed markedly in their
therapeutic response to CY.
This bioassay for CY is a relatively simple and rapid procedure, and the extension of its application from
body fluids to solid tissues makes it a useful tool in experimental pharmacokinetic studies.
The sensitivity of animal tumours to chemotherapy
with cyclophosphamide (CY) varies markedly with
tumour type (Steel, 1977). In our own laboratory,
we have also found significant variations in
response to CY when a tumour of one type was
grown in different sites (Begg & Smith, 1981). A
third factor known to affect response to chemo-
therapy is the size of the tumour at treatment (Steel
& Adams, 1975; Twentyman & Bleehen, 1976; Fu
et al., 1979). These observations suuggest that there
is no inherent biochemical property that is solely
responsible for determining a tumour's sensitivity to
CY. One factor that may influence chemothera-
peutic efficacy is the amount of drug delivered to
the tumour. This communication is therefore
concerned with the development of a technique to
measure cytotoxic drug concentrations in tumours
in order that correlations with chemosensitivity can
be made.
CY undergoes conversion in the liver to several
cytotoxic and to several non-cytotoxic metabolites
(Brock & Hohorst, 1967; Connors et al., 1970;
Sladek, 1971). These metabolites can be detected
using chemical or chromatographic techniques
(Sladek, 1971; Fenselau et al., 1977), or by a
bioassay method using animals or tissue culture
(Sladek, 1973; Weaver, 1978; Tannock, 1980). The
advantages of a bioassay are (1) it measures only
the cytotoxic metabolites, i.e. most relevant for
comparisons with tumour cell killing, and (2) it can
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be carried out in laboratories not equipped with
High Performance Liquid Chromatography, or
similar analytical equipment.
Sladek (1973) described a bioassay for measuring
CY metabolite levels in rat blood and urine in
which he treated tumour cells in vitro with these
fluids and assayed by survival time of rats
inoculated with the treated cells. A purely in vitro
bioassay was subsequently described by Weaver et
al. (1979) using growth inhibition of L1210 cells in
1978 culture. The present report describes a
bioassay for CY using colony formation in vitro as
the endpoint. A similar method has been described,
for blood only, by Tannock (1980). We have
extended the observations on blood, and
subsequently developed the assay for two different
tumour types and for normal mouse lungs. The
development of a bioassay to detect metabolite
levels in solid tissues has not previously been
reported.
Materials and methods
Mice and tumours
The two mouse strains used in these studies were
CBA/HtGyfBSVS and WHT/GyfBSVS. The two
tumours studied arose spontaneously and have been
maintained by subcutaneous transplantation in the
strain of origin. They are the CBA SA F, an
anaplastic fast growing tumour, and the WH SA
FA, a slower growing fibrosarcoma, chosen because
of their markedly different sensitivities to CY. The
specific growth delays (growth delay/doubling time)
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were 4.5 and 0.5 for the SA F and the SA FA
respectively after 110mgkg-1. The tumours were
used when they reached - 10mm mean diameter.
Drug
The cyclophosphamide (Cytoxan, CY) used in these
studies was kindly donated by Ward Blenkinsop
Pharmaceuticals, Bracknell, Berks. The drug was
dissolved in 0.9% saline and injected intraperi-
toneally to give doses up to 400mgkg 1.
Cell culture
Chinese hamster V79-379A cells were maintained in
suspension culture and taken for the bioassay
experiments when in log phase (between 2 x 105 and
8 x I05cellsml-1). The cells were counted under
phase contrast in a haemocytometer and diluted
with Eagles MEM plus 10% foetal calf serum
(complete medium). One ml aliquots of the cell
suspensions were plated in 25cm2 plastic petri
dishes containing 3ml of prewarmed complete
medium. After allowing 2-5 h for attachment, 1 ml
of blood or tissue extract (described below) was
added. After varying times at 37°C (the treatment
period) the cells were washed twice, 5ml of fresh
medium added, and the cells incubated for 7 days
to allow colony formation.
Bioassay method
The method for detecting blood levels of CY was
as follows. Mice were anaesthetized by inhalation
of Penthrane (methoxyfluorane) at a given time
after CY injection, and blood was taken from the
thoracic cavity after cutting the aorta. The
extracted blood was heparinized and kept at 40C
until processed. It was then diluted 1 in 6 (unless
otherwise stated) with complete medium and
centrifuged at 1800g for 15min. The supernatant
comprised diluted plasma which contained CY
metabolites and was used to treat log phase V79
cells as described above. The dilution of the plasma
under standard conditions was 1/55. This resulted
from diluting whole blood 1/6, equivalent to
diluting the plasma 1/11. A further dilution of 1/5
was made on adding 1 ml of the diluted plasma to
4ml medium in each petri dish.
The method for extracting CY metabolites from
tumours and from lungs will be described in the
following section.
Results
Blood levels
The survival of V79 cells as a function of treatment
time with plasma from control and CY injected
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Figure 1 Kinetics of cytotoxicity of plasma from
untreated mice (open symbols) or from mice sacrificed
10-15min after 200mgkg-1 CY (closed symbols). The
untreated plasma showed little cytotoxicity to V79-
379A cells for up to 24h incubation at 37°C. Plasma
from CY treated mice was highly toxic. Each point
represents the mean of 2 dishes. Different symbols
represent separate experiments.
mice is shown in Figure 1. Little toxicity was seen
with exposure to diluted plasma from control mice
for times up to 24h. Plasma from mice given
200mgkg 1 CY, however, was highly toxic. The
survival curve appeared to flatten progressively
with time, with most of the cell killing occurring in
the first 8h.
Dose response curves for V79 cell killing as a
function of CY dose are shown in Figure 2. For
panel a, blood was extracted 10min after graded
doses of CY. The standard plasma dilution factor
(1/55) was used for all doses. For panel b, a
constant dose of CY was injected (see legend),
blood was taken 10min later, and the plasma
diluted 1/55. Further dilutions were then made to
provide the different concentrations of activated
CY. For both dose response curves there was a
significant shoulder in the low dose region followed
by an exponential region. Significant cell killing was
seen with doses above 50mgkg- I (panel a).
In order to test the sensitivity of the bioassay, an
experiment was carried out in which the plasma
dilution factor was decreased. Table I shows that
cytotoxic metabolites could be detected in the blood
after injection of a dose as low as 10mgkg 1 if the
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Figure 2 (a) Cytotoxicity of plasma from mice
receiving graded doses of CY 10-15min before
sacrifice. * and A are from separate experiments. (b)
Cytotoxicity of plasma from mice receiving a constant
dose of CY 10-15min before sacrifice, followed by
serial dilutions before treatment in vitro.
0 =400mgkg-1, 2h exposure in vitro;
A=200mgkg-1, 18h exposure. A dilution factor of
1.0 represents the standard 1/55 dilution of the plasma
from which further dilutions were made.
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Table I Sensitivity of the bioassay: detection of low
levels of CY metabolites in blood
Survivingfractiona
Plasma
CY dose dilution
(mgkg-1) factor: 1 5 15 55
0 0.32 0.80 1.25
10 0.0088 0.087 0.92 0.92
aBlood was extracted 10min after CY injection i.p., and
the plasma diluted and used to treat log phase V79 cells
for 18h at 37°C. Surviving fractions were assayed by
colony formation 7 days later.
plasma was either not diluted, or only diluted by
1/5. Direct addition of undiluted plasma to V79
cells from which the overlying medium had been
removed resulted in some toxicity with plasma from
control animals, but the toxicity of CY-containing
plasma was much greater.
Results of experiments in which the time of
taking the blood sample after CY injection was
varied are shown in Figure 3. These experiments
define the pharmacokinetics of the cytotoxic meta-
b
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Figure 3 Pharmacokinetics of CY metabolites in blood. (a) Plasma taken 10-20min after injection of
200mgkg-1 was most cytotoxic. By 45min the cytotoxicity was lost. (18h exposure in vitro). (b) Maximum
cytotoxicity occurred 15-30min after 400mgkg-' (2h exposure in vitro).
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bolites in plasma after administering 200 and
400mgkg- CY i.p. Maximum blood
concentrations of cytotoxic metabolites (minimum
surviving fractions) were achieved approximately
10min after 200mgkg-t and 15min after
400mgkg-1. After the higher dose the maximum
cytotoxicity lasted for a longer period. This suggests
slower clearance (excretion or catabolism) of the
active metabolites after higher doses.
Tumour levels
One of the principal aims of this study was to
measure the concentrations of CY metabolites in
tumours. We therefore adapted the method
described above, which had been demonstrated to
be satisfactory for determining blood levels, to solid
tumours. Several methods were tried until a
satisfactory technique was developed. A relatively
simple procedure was found to give the best results.
The tumour was weighed, minced finely with
scissors if it was soft and broke up easily, or cut
into small pieces using scalpel blades if it was hard
and fibrous. Complete medium was added to the
mince to a give a tumour weight/final volume ratio
of 1/10. The mixture was incubated at room
temperature for 10min with continuous shaking to
extract the cytotoxic metabolites, followed by
centrifugation at 10,000rpm for 30min at 4°C. The
supernatant was used to treat monolayer log phase
V79 cells for up to 4h at 370C.
Most of the extraction of CY metabolites from
the tumour occurred when the tumour mince was
incubated in medium at room temperature before
the centrifugation step. A 10min incubation
provided a more cytotoxic supernatant (minimum
surviving fraction ratio) than 0 or 60min (Table II).
Table II Effect of extraction time for SA FA
tumours
Survivingfraction
Minutes extractiona
CYdose (mgkg1) 0 10 60
0 0.95 0.65 0.68
400 0.79 0.085 0.21
S.F. ratiob 0.83 0.13 0.31
aTumours were excised 30min after i.p. CY
injection. The tumour mince was diluted to 1/10
with complete medium and incubated at room
temperature with continuous shaking for the times
shown. After centrifigation (10,000rpm, 30min,
4°C) the diluted supernatants (1/5) were used to
treat V79 cells for 3.5h at 37°C. Surviving fractions
are means from 2 plates.
bRatio of surviving fractions treated/untreated.
The smaller cytotoxicity after 60min may have
resulted from degradation in vitro of the extracted
metabolites.
A range of centrifugation speeds giving resultant
forces between 2,500 and 76,000gav were tested.
Cloudy supernatants were produced by 2500g, and
such supernatants from control tumours were
highly cytotoxic to V79 cells. Forces greater than
14,000g produced clear supernatants from
untreated tumours and which were considerably less
toxic; 14,000g was therefore used in all subsequent
experiments. Surviving fractions significantly < 1.0
were only seen with control tumour extracts when
incubation times longer than 3-4h were used
(Figure 4). By 6-8h the extracts caused extensive
cell killing. A maximum treatment period of 4h
was therefore chosen.
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Figure 4 Cytotoxicity of extracts from control
tumours, i.e. with no cyclophosphamide. These
extracts were relatively non-toxic for 3-4h. Tumours:
*=CBA SA F; *=WH SA FA.
This procedure was tested on on two types of
murine tumour differing in histology and sensitivity
to CY (Figure 5). The CBA SA F is fast growing,
easy to break up and CY sensitive, whereas the
WH SA FA is slower growing, hard, fibrous, and
CY resistant. The bioassay worked well on both
tumours with significant quantities of CY meta-
bolites extracted from each. Maximum tumour
metabolite levels occurred at approximately 45min
after i.p. injection, significantly later than in blood.
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Figure 5 Pharmacokinetics of CY metabolites in
tumours after 400mgkg-1. Maximum cytotoxicity was
seen at 45min in both tumours and some activity
persisted at 120min. A in vitro treatment for 3.5h. S
in vitro treatment for 4.0h.
Mouse lungs
The bioassay procedure developed for tumours was
also tested on normal mouse lungs. CY metabolites
could be extracted from lungs using the same
procedure, with maximum cytotoxicity occurring
for tissues taken between 5 and 15min after
injection (Figure 6).
Pharmacokinetics
In order to determine the biological half life of the
active CY metabolites it was necessary to convert
surviving fraction values into CY concentration
values. This was done using dose response curves
such as those shown in Figure 2. For a pharmaco-
kinetic experiment employing a given in vitro
treatment time (e.g. 4h), each S.F. value is
converted to a mgkg-1 value by reading off a dose
response curve obtained using that treatment time.
The conversion gives the relative concentrations of
CY metabolites at the different sampling times. The
results of experiments on blood, tumour and lungs
using this conversion are shown in Figure 7. The
data from 2 experiments with the CBA SA F
showed no consistent differences from those of 3
experiments with WH SA FA tumours. All 5 sets of
data were therefore pooled.
High levels of CY metabolites appeared in the
blood by 5min and were maximal 15min after
injection (Figure 7). The levels began to decline by
c
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Figure 6 Pharmacokinetics of CY metabolites in
mouse lung. Maximum cytotoxicity was seen at 10min
and all activity was lost by 90min. (400mgkg-1; 3.5h
exposure in vitro).
45min with an initial half life of -14min. At later
times after injection the half life was decreased to
9min. In the tumours, drug levels reached a
maximum later (30-45min) and declined more
slowly (T-=61min) than those in blood. In lungs,
maximum levels were reached within 5min of
injection, the earliest time tested. After 15min the
levels declined with a half life of 35min. Beyond
1 h, metabolite concentrations were difficult to
determine, since surviving fractions approached 1.0,
indicating that very little drug remained. The half.
life at these later times was estimated to be 11 min
or less.
Discussion
The ease with which cytotoxic metabolites of CY
could be extracted and used to kill V79 cells in
culture suggests that they do not bind significantly
to proteins either in the plasma or in the tissue
culture medium, or that they bind only loosely and
reversibly. This is consistent with the results of
others (Cox et al., 1975). The pure drug and its
metabolites are evidently freely diffusible and lipid
soluble since large quantities of cytotoxic meta-
bolites appear in the blood and lung within 5min
of an i.p. injection.
Further evidence of the low binding and lipid
soluble nature of the metabolites is that they could
be extracted into the surrounding medium as easily
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Figure 7 Pharmacokinetics of CY metabolites in blood, tumour and lung. The "effective CY dose" was
obtained by converting surviving fractions (Figures 3, 5 and 6) to CY dose from dose response curves (Figure
2a). In blood and lung two clearance rates were detectable. In the tumour the initial clearance rate was much
slower. Points represent pooled data from 4-6 experiments; errors are + 1 s.e. The numbers against each curve
are the half lives in min + 1 s.e. calculated using linear regression analyses.
from a tumour mince containing -1 mm cube
pieces, as from a suspension containing broken or
permeabilized cells (data not shown). Similar
amounts of cytotoxic metabolites could also be
extracted from hard fibrous tumours, in which it is
difficult to make a cell suspension (WH SA FA), as
from "soft" tumours which are easily broken up
(CBA SA F). It was of interest that the more
sensitive to CY of the two tumours showed, if
anything, the lower concentration of metabolites.
This correlates with a slightly lower blood flow in
CBA SA F tumours, as will be discussed more fully
in a separate report (A.C. Begg & K.A. Smith, in
preparation).
The direct comparison of tumour levels assumes
that the fraction of metabolites extracted from each
tumour type is the same. This is not proven,
although it is probably reasonable given the
properties of the metabolites discussed above. Time
course comparisons can be made since these are
independent of the extracted fraction.
The pharmacokinetic results for blood indicated
that maximum concentrations were achieved
rapidly, and that the half life appeared to decrease
progressively with time, consistent with there being
saturation of the enzymes responsible for
degradation at these high doses of CY. These
results are similar to others using chemical
detection methods on mouse blood. Domeyer &
Sladek (1980) found maximum levels of hydroxy-
cyclophosphamide 5min after 65mgkg-1 in BDF
mice. They found half lives of -20min for this
metabolite and -30min for the parent compound
-I h after injection (estimated from their published
curves). Hydroxy-cyclophosphamide is the
transport precursor form of the cytotoxic meta-
bolites and probably the most active in vitro
(Brock, 1976). Olivera (1971) has also reported a
half life of CY in mice between 17 and 25min.
These values are similar to those reported here:
using the bioassay.
The pharmacokinetic results for 2 different
tumours showed that the clearance of cytotoxic
metabolites was considerably slower than in blood
or lung. The exposure dose (concentration x time
integral) to the tumour would consequently be
underestimated from blood data. The slower
clearance may reflect the greater intercapillary and
thus diffusion distances occurring in tumours
compared with most normal tissues. An alternative
possibility is that there is a lower concentration of
enzymes in tumours capable of converting 4-
3
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hydroxy cyclophosphamide to non-toxic meta-
bolites. The data cannot distinguish between these
possibilities.
In conclusion, the bioassay is a fairly simple
procedure for studying the pharmacokinetics of CY
metabolites not only in blood, but in "solid"
normal tissues, and in tumours. Little data has been
published on the pharmacokinetics of CY in other
than blood or urine. The present method allows
comparative pharmacokinetic data to be obtained
in other tissues.
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